Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Andrew Moreno
Second-Line ITP Management: How Might New Therapies Change Practice?
About the newest pharmacotherapy mechanisms of action under clinical investigation in the second-line setting, Heme Today asked Dr. Broome and Dr. Cuker which ones have piqued ITP clinicians’ interest. Two drug classes mentioned by both experts in their written remarks were B-cell-activating factor (BAFF) inhibitors and anti-CD38 monoclonal antibodies.
Gene Therapy among Current SCD Management Intervention Options
On what is gene therapy’s greatest significance for SCD management, all three experts in their written responses to Heme Today explained that it offers patients a dramatically effective, potentially curative, clinical option.
Dr. Hans-Peter Kiem’s Vision for the Future of Gene and Cell Therapy
From developing genetically modified stem cells to leading the in vivo revolution in gene therapy, Hans-Peter Kiem, MD, PhD, aims to develop curative treatments for patients with genetic diseases and hematologic malignancies.
AI in Modern Hematology: Insights from Clinical Applications in Myelofibrosis
One researcher is Adrián Mosquera Orgueira, MD, PhD, a hematologist and cancer genomics expert at the University Hospital of Santiago de Compostela, Spain, and group leader for Computational and Genomic Hematology at the Health Research Institute of Santiago de Compostela.
One Year Into Isatuximab-Iberdomide Maintenance for ND, ASCT-Eligible Multiple Myeloma
In this population, MIDAS is testing a 3-year intensified maintenance therapy of isatuximab plus iberdomide. Results from the first year of this approach with the doublet were released at the International Myeloma Society 23rd Annual Meeting and Exposition in Glasgow, Scotland. The findings have been encouraging and the study team, led by first author Aurore Perrot, MD, PhD, of the Cancer Research Center of Toulouse, France, presented these in an abstract published online ahead of the meeting.
Phase 1b Study Brings Dosing Insights on Cevostamab for Relapsed, Refractory MM
In an abstract of the study published online for the Meeting, first author Amrita Y Krishnan, MD, of City of Hope Cancer Center in Orange County, California, and colleagues wrote that “A fixed-duration, modified cevostamab dosing regimen induces durable remissions that continue after treatment completion in BCMA-naïve pts with RRMM [relapsed or refractory multiple myeloma].
Adult Burkitt Lymphoma: A Clinician Presentation Overviews the Disease
The National Comprehensive Cancer Network (NCCN) 2026 Annual Congress: Hematologic Malignancies featured on its meeting digital platform a multifaceted presentation on Burkitt lymphoma in adult patients. It was given by Sunita D Nasta, MD, the chief of the Lymphoma Section in the Division of Hematology-Oncology at the University of Pennsylvania’s Abramson Cancer Center in Philadelphia.
Hermann Einsele, MD, on the Variety of Available Therapy Approaches in Multiple Myeloma
At the 17th Annual International Myeloma Working Group (IMWG) Summit, which convened in Stockholm, Sweden, the International Myeloma Foundation (IMF) honored the 2026 recipient of the Robert A Kyle Lifetime Achievement Award, Hermann Einsele, MD.1 A hematologic oncologist with a clinical research career that spans decades, Dr. Einsele’s work has contributed to progress in several types of multiple myeloma therapy, especially stem cell transplantation.
CAR T-Cell Therapy for Kappa-Restricted Multiple Myeloma: First Trial Patient Dosed
In kappa-restricted multiple myeloma, malignant cells feature KMA tumor receptors, which can be targeted by treatment. The phase 1 clinical trial KOALA1 is evaluating a novel agent that hones this mechanism of action in patients with relapsed or refractory disease.
Phase 2 OPTI-AML Trial: Is Shortening Venetoclax in Azacitidine-Venetoclax AML Doublet Beneficial?
OPTI-AML was conducted by a team of US-based clinical investigators led by Uma M Borate, MBBS, of The Ohio State University in Columbus, and published their findings in Blood.1 In written remarks forwarded to Blood Cancers Today, Dr. Borate and coauthor Shivani Handa, MD, also of The Ohio State University, together elaborated on the study.
Interim Prospective Study Data Reported on Pirtobrutinib Plus Obinutuzumab for Untreated CLL
These results are featured within the interim data released by the study investigator team for the European Hematology Association (EHA) 2026 Congress. The team published their findings online in an abstract written for the Congress, and lead author Inhye E Ahn, MD, of Dana-Farber Cancer Institute in Boston, Massachusetts, presented their study at the on-site event in Stockholm, Sweden.
Complete Response Predictive for Overall Survival in Relapsed, Refractory LBCL, Real-World Data Suggest
In relapsed or refractory large B-cell lymphoma (LBCL), a patient’s complete response (CR) to treatment may help the managing clinician estimate the patient’s ultimate overall survival (OS). Findings from a two-component investigation by a team of researchers from US-based clinical institutions suggest this. Led by Armin Ghobadi, MD, of Washington University in St. Louis, Missouri, the team published its findings in Transplantation and Cellular Therapy.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Andrew
Contact Andrew, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack